na-931 vs retatrutide The NEW Ozempic Replacements: Retatrutide, Orforglipron & Maritide EXPLAINED! Retatrutide vs. Tirzepatide: The New
Description
Generally, their effects have been demonstrated in clinical trials in overweight and obese populations, which usually present other risk factors such as hypertension prediabetes/type 2 diabetes, dyslipidemia, and moderate or severe obstructive sleep apnea

Each year, the KFF conducts a survey to examine trends in employer-sponsored health benefits
In 2019, the REWIND trial found that in the 9901 patients with T2DM with and without previous CVD randomly assigned to a once-weekly 1.5 mg dulaglutide injection or placebo (median follow-up 5.4 years), three-point MACE occurred in 594 patients receiving dulaglutide (12.0%) and in 663 patients (13.4%) in the placebo group, which included a significant decrease in the rate of non-fatal stroke (Gerstein et al

Weve spent the last two years drawing on Nooms deep expertise in behavior change to create the ultimate GLP-1 companion program to solve the medications twin challenges, persistence and muscle-mass loss, while also driving enhanced weight loss outcomes

Excited to keep going at the low dose
Conclusions Evidence accrued so far suggest that GLP-1RA could exert a modest renal benefit alongside CV protection, justifying its place as second-line drug in patients with T2D and CKD not achieving glycemic control with SGLT-2i and metformin according to KDIGO guidelines [87]